In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11

Anti-Cancer Drugs

Volumn 8, Issue 3, 1997, Pages 238-244

  Maier, Jeanette A M ^a   Delia, Domenico ^b   Thorpe, Philip E ^c   Gasparini, Giampietro ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

angiogenesis; angiogenesis inhibitors; human endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOGLIN; ENDOGLIN ANTIBODY; FUMAGILLOL CHLOROACETYLCARBAMATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TEC 11; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CELL TYPE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; CULTURE MEDIA; CYCLOHEXANES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIUM, VASCULAR; HUMANS; INDICATORS AND REAGENTS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATORS; SESQUITERPENES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030932552     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199703000-00004     Document Type: Article

References (36)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell 1994; 79: 315-28.
3. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1: 149-53.
4. Gasparini G. Quantification of intratumoral vascularisation predicts metastasis in human invasive solid tumours. Oncol Rep 1994; 1: 7-12.
5. Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82.
6. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
7. Gasparini G, Harris AL. Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 1994; 30A: 201-6.
8. Folkman J. Tumour Angiogenesis. In: Holland J, Frei E, Bast RC, et al., eds. Cancer medicine, IV edn. Melbourne, PA: Lea and Febiger 1993; 153-71.
9. Gasparini G. Anagiogenesis research up to 1996. A commentary of the state of art and suggestions for future studies. Eur J Cancer 1997; 32A: 2379-85.
10. Ingber D, Fujita T, Kishimoto S, et al. Synthetic-analogues of fumagallin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7
11. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo MK, Fujita T. Inhibition of tumour growth and metastasis of rodent tumours by the angiogenesis inhibitor O-(chlorocetyl-carbomoyl)fumagillol (AGM-1470; AGM-1470). Cancer Res 1993; 53: 4262-7
12. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor AGM-1470 on tumour growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53: 2566-70.
13. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumour growth and metastasis. J Ped Surg 1993; 28: 1253-7.
14. Kusaka M, Sudo K, Fujita T, et al. Potent antiangiogenic action of AGM-1470: comparison to the fumagallin parent. Biochem Biophys Res Commun 1991; 174: 1070-6.
15. Tanaka T, Konno H, Matsuda I, Nakamura E, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor AGM-1470. Cancer Res 1995; 55: 836-9.
16. Folkman J. Tumour angiogenesis: a possible control point in tumour growth. Ann Int Med 1975; 82: 96-100.
17. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995; 36: 237-51.
18. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumour growth by immunoneutralizing monoclonul antibody angainst human basic fibroblast growth factor. Cancer Res 1991; 51, 6180-4.
19. Kim KJ, Li B, Winer J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1994; 362: 841-4.
20. Weinstat-Saslow DL, Zebrentzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin-1 complementary DNA into a human breast carcinoma cell line reduces primary tumour growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11.
21. Maier JAM, Statuto M, Ragnotti G. Endogenous interleukin 1 must be translocated to the nucleons to exert its biological activity in human endothelial cells. Mol Cell Biol 1994; 14: 1845-51.
22. Takahashi K, Sawasaki Y, Hata J, Mukai K, Goto T. Spontaneous tranformation and immortalization of human endothelial cells. In Vivo Cell Dev Biol 1990; 25: 265-74.
23. Maciag T, Hoover GA, Stemerman MB, Weinstein R. Serial propagation of human endothelial cells in vitro. J Cell Biol 1981; 91: 420-6.
24. Maier JAM, Presta M, Ragnotti G. Induction of plasminogen activators by phorbol esters in bovine endothelial cells. Possible independence from protein kinase C. Biochem Biophys Res Commun 1989; 160: 682-91.
25. Presta M, Maier JAM, Rusnati M, Moscatelli D, Rangotti G. Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by bFGF and TGFβ. Cancer Res 1988; 46: 6384-9.
26. Brem H, Ingber D, Blood CH, Bradley D, Urioste S, Folkman J. Suppression of tumour metastasis by angiogenesis inhibition. Surgical Forum 1991; 42: 439-41.
27. 1 phase of the cell cycle. Cancer Res 1994; 54: 2073-6.
28. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogencsis inhibitor AGM-1470 (AGM-1470). Br J Cancer 1994; 69: 212-6.
29. Abe J. Zhou W, Takuwa N, et al. A fumagallin-derivative angiogenesis inhibitor, AGM-1470, inhibits activiation of cyclin-dependent kinases and phosphory-lation of retinoblastoma gene product, but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54: 3407-12.
30. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
31. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNPα Modulation by inhibitors of protein synthesis. Exp Cell Res 1994; 214: 548-94.
32. Gougos A, Letarte M. Primary structure of endoglin. an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1992; 265: 8361-4.
33. Cheifetz S, Bellòn R, Calés C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-30.
34. Jennings JC, Mohan S, Linkhart TA, Widstrom R, Baylink DJ. Comparison of the biological actions of TGFβ1 and TGFβ2 and differential actions in endothelial cells. J Cell Physiol 1988; 137: 167-72.
35. cheifetz S, Hernandex H, Laiho M, Ten Dijke P, Iwata KK, Massague J. Distinct TGFβ receptor subsets as determinants of cellular responsiveness to three TGFβ isoforms. J Biol Chem 1990; 265: 20533-8.
36. Merwin JR, Newman W, Beall LD, Tucker A, Madri J. Vascular cells respond differentially to TGFβ1 and TGFβ2 in vitro. Am J Pathol 1991; 138: 37-51.